AD vs. | Calculated cut-offs | Sensitivity (95% CI) [%] | Specificity (95% CI) [%] | AUCs (95% CI) | Positive likelihood ratio | |
---|---|---|---|---|---|---|
CSF VILIP-1 | ND | >116 | 78 (67–86) | 63 (50–73) | 0.77 (0.70–0.85) | 2 |
Con | >129 | 70 (59–79) | 88 (79–94) | 0.87 (0.82–0.93) | 6 | |
Serum VILIP-1 | ND | >32 | 58 (46–68) | 67 (55–77) | 0.59 (0.50–0.69) | 2 |
Con | >30 | 63 (52–73) | 72 (61–81) | 0.69 (0.60–0.77) | 2 | |
CSF t-tau | ND | >392 | 100 (95–100) | 80 (68–88) | 0.95 (0.92–0.99) | 5 |
Con | >399 | 100 (95–100) | 93 (85–97) | 0.99 (0.98–100) | 15 | |
CSF p-tau 181 | ND | >94 | 95 (87–98) | 98 (92–99) | 0.98 (0.97–1) | 59 |
Con | >93 | 95 (87–98) | 99 (92–100) | 0.99 (0.98–1) | 65 | |
CSF Abeta 1-42 | ND | <733 | 96 (89–99) | 75 (63–84) | 0.88 (0.83–0.94) | 4 |
Con | <689 | 92 (83–96) | 87 (77–93) | 0.95 (0.92–0.98) | 7 | |
CSF VILIP-1/CSF Abeta 1-42 | ND | >0.174 | 97 (91–100) | 83 (72–90) | 0.93 (0.89–0.97) | 6 |
Con | >0.169 | 97 (91–100) | 91 (82–95) | 0.98 (0.97–1) | 10 | |
Serum VILIP-1/CSF Abeta 1-42 | ND | >0.048 | 74 (63–83) | 77 (65–85) | 0.81 (0.74–0.89) | 3 |
Con | >0.037 | 88 (78–93) | 80 (70–88) | 0.89 (0.84–0.95) | 4 | |
CSF t-tau/CSF Abeta 1-42 | ND | >0.775 | 92 (83–96) | 95 (87–99) | 0.98 (0.96–1) | 20 |
Con | >0.53 | 100 (95–100) | 96 (89–99) | 0.99 (0.99–1) | 25 | |
CSF p-tau 181/CSF Abeta 1-42 | ND | >0.120 | 93 (85–97) | 94 (85–98) | 0.98 (0.96–1) | 15 |
Con | >0.1 | 99 (93–100) | 91 (82–96) | 0.99 (0.98–1) | 11 |